Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof

• US 7,479,282 B2
• Filed: 01/05/2004
• Issued: 01/20/2009
• Est. Priority Date: 04/07/1998
• Status: Expired due to Fees

• Current Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories), Medimmune (Astrazeneca PLC)
• Original Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories), Medimmune (Astrazeneca PLC)
• Inventors: Tuomanen, Elaine I., Wizemann, Theresa M., Masure, H. Robert, Johnson, Leslie S., Koenig, Scott
• Primary Examiner(s): MINNIFIELD, NITA M
• Application Number:
  US10/751,702
• Publication Number:
  US 20040120966A1
• Time in Patent Office: 1,842 Days
• Field of Search: 530/350, 530/324, 424/184.1, 424/190.1, 424/234.1, 424/244.1, 424/185.1, 424/236.1, 424/237.1, 424/690, 424/698, 514/2
• US Class Current: 424/244.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07K 14/3156 from Streptococcus pneumoniae (Pneumococcus) Streptokinase C07K14/3153

Abstract

This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO: 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate. Lastly, this invention provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use.

Claims

1. A vaccine for treating or protecting against pneumococcal infection comprising a polypeptide in a pharmaceutically acceptable carrier wherein said polypeptide comprises SEQ ID NO:

4, said polypeptide does not bind to choline, said polypeptide exhibits a tertiary structure as found in a native, full-length CbpA polypeptide, and the polypeptide content of said vaccine being in an amount effective for treating or protecting against R6x pneumococcal infection or Type 4 pneumococcal infection.

2. The vaccine of claim 1, wherein said vaccine when administered elicits an antibody that protects against pneumococcal infection in a mammal.

3. The vaccine of claim 2 wherein said mammal is a human.

4. The vaccine of claim 1, wherein said vaccine further comprises an adjuvant.